Detalhe da pesquisa
1.
Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.
J Pharmacol Exp Ther
; 363(3): 377-393, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28954811
2.
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
Clin Cancer Res
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819400
3.
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
J Med Chem
; 67(2): 1262-1313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38180485
4.
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Mol Ther Nucleic Acids
; 29: 625-642, 2022 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36090761
5.
Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.
PLoS One
; 12(12): e0187609, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29261656
6.
Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains.
Neuropsychopharmacology
; 41(2): 568-77, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26105137